Asthma 2008: Targeting Immunoglobulin E to Achieve Disease Control

References

• National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD 1997, NIH publication 97-4051
   Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics 2002. National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD 2003, NIH publication 02-5047
   Google Scholar
• National Asthma Education and Prevention Program, http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full report 2007. Accessed December 17, 2007
   Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD 2005, NIH publication 02-3659
   Google Scholar
• American Lung Association Epidemiology and Statistics Unit. Trends in asthma morbidity and mortality. 2006, Available at: www.lungusa.org/atf/cf/7A8D42C2-FCCA-4604-8ADE-7F5D5E762256/ASTHMA06FINAL.PDF Accessed December 17, 2007
   Google Scholar
• Miller M K, Johnson C, Miller D P, , for the TENOR Study Group, et al. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol 2005; 116: 990–995
   PubMed Web of Science ®Google Scholar
• Bateman E D, Boushey H A, Bousquet J, , for the GOAL Investigators Group, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004; 170: 836–844
   PubMed Web of Science ®Google Scholar
• Dolan C M, Fraher K E, Bleecker E R, , for the TENOR Study Group, et al. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92: 32–39
   PubMed Web of Science ®Google Scholar
• Stempel D A, McLaughin T P, Stanford R H, Fuhlbrigge A L. Patterns of asthma control: a 3-year analysis of patient claims. J Allergy Clin Immunol 2005; 115: 935–939
   PubMed Web of Science ®Google Scholar
• Peters S P, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100: 1139–1151
   PubMed Web of Science ®Google Scholar
• Szefler S J, Martin R J, King T S, , for the Asthma Clinical Research Network of the National Heart, Lung and Blood Institute, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410–418
   PubMed Web of Science ®Google Scholar
• Morrow T J. Implications of pharmacogenomics in the current and future treatment of asthma. J Manag Care Pharm 2007; 13: 497–505
   Google Scholar
• Roland N J, Bhalla R K, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126: 213–219
   PubMed Web of Science ®Google Scholar
• Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006; 61: 518–526
   PubMed Web of Science ®Google Scholar
• Israel E, Chinchilli V M, Ford J G, , for the National Heart, et al. Lung and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet 2004; 364: 1505–1512
   PubMed Web of Science ®Google Scholar
• Wechsler M E, Lehman E, Lazarus S C, , for the National Heart, et al. Lung and Blood Institute's Asthma Clinical Research Network. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519–526
   PubMed Web of Science ®Google Scholar
• Nelson H S, Weiss S T, Bleecker E R, Yancey S W, Dorinsky P M, for the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, Available at: www.fda.gov/cder/drug/advisory/LABA.htm FDA public health advisory. Updated May 15, 2006. Accessed December 17, 2007
   Google Scholar
• Li J T, Oppenheimer J, Bernstein I L, Nicklas R A. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005; 116(6 suppl)S3–S11
   Google Scholar
• Teeter J G, Bleecker E R. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998; 113: 272–277
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu C, Holgate S T, Reiss T F. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J 2002; 20: 1102–1109
   PubMed Web of Science ®Google Scholar
• Peters S P, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100: 1139–1151
   PubMed Web of Science ®Google Scholar
• Nathan R A, Sorkness C A, Kosinski M, et al. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59–65
   PubMed Web of Science ®Google Scholar
• Stoloff S W, Boushey H A. Severity, control, and responsiveness in asthma. J Allergy Clin Immunol 2006; 117: 544–548
   PubMed Web of Science ®Google Scholar
• Burrows B, Martinez F D, Halonen M, Barbee R A, Cline M G. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271–277
   PubMed Web of Science ®Google Scholar
• Sunyer J, Antó J M, Castellsagué J, Soriano J B, Roca J. Total serum IgE is associated with asthma independently of specific IgE levels. Eur Respir J 1996; 9: 1880–1884
   PubMedGoogle Scholar
• Sears M R, Burrows B, Flannery E M, Herbison G P, Hewitt C J, Holdaway M D. Relation between airway hyperresponsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325: 1067–1071
   PubMed Web of Science ®Google Scholar
• Sherrill D L, Stein R, Halonen M, Holberg C J, Wright A, Martinez F D. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. J Allergy Clin Immunol 1999; 104: 28–36
   PubMed Web of Science ®Google Scholar
• Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan C M, for the TENOR Study Group. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2005; 95: 247–253
   PubMed Web of Science ®Google Scholar
• Busse W W, Lemanske R F. Asthma. N Engl J Med 2001; 344: 350–362
   PubMed Web of Science ®Google Scholar
• Storms W. Allergens in the pathogenesis of asthma: potential role of anti-immunoglobulin E therapy. Am J Respir Med 2002; 1: 361–368
   PubMedGoogle Scholar
• Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269: 26368–26373
   PubMed Web of Science ®Google Scholar
• Conner E R, Saini S S. The immunoglobulin E receptor: expression and regulation. Curr Allergy Asthma Rep 2005; 5: 191–196
   Google Scholar
• Platts-Mills T AE. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164: S1–S5, (8 Pt 2)
   PubMed Web of Science ®Google Scholar
• Bousquet J, Jeffery P K, Busse W W, Johnson M, Vignola A M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720–1745
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier B Q, et al. Omalizumab, an anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–190
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459–465
   PubMed Web of Science ®Google Scholar
• Beck L A, Marcotte G V, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol 2004; 114: 527–530
   PubMed Web of Science ®Google Scholar
• Xolair [package insert]. Genentech, Inc., South San Francisco, CA 2007, East Hanover, NJ: Novartis Pharmaceuticals Corporation
   Google Scholar
• Berry M A, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 2006; 354: 697–708
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–261
   PubMed Web of Science ®Google Scholar
• Holgate S T, Chuchalin A G, Hébert J, , for the Omalizumab 011 International Study Group, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632–638
   PubMed Web of Science ®Google Scholar
• Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73–78
   PubMed Web of Science ®Google Scholar
• Lanier B Q, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 154–159
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–316
   PubMed Web of Science ®Google Scholar
• Ayres J G, Higgins B, Chilvers E R, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701–708
   PubMed Web of Science ®Google Scholar
• Busse W W, Massanari M, Kianifard F, Geba G P. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Current Med Res Opin 2007; 23: 2379–2386
   PubMed Web of Science ®Google Scholar
• Niebauer K, Dewilde S, Fox-Rushby J, Revicki D A. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006; 96: 316–326
   PubMed Web of Science ®Google Scholar
• Busse W W. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164: S12–S17, (8 Pt 2)
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20: 1088–1094
   PubMed Web of Science ®Google Scholar
• Deniz Y M, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005; 29: 31–48
   PubMed Web of Science ®Google Scholar
• Price K S, Hamilton R G. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28: 313–319
   PubMed Web of Science ®Google Scholar
• Varghese M, Lieberman P. The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen. Allergy Asthma Proc 2007; 28: 320–323
   Google Scholar
• Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378–1386
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, Chung K F, Berger W, Fox H, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 1483–1492
   PubMed Web of Science ®Google Scholar
• Wu A C, Paltiel A D, Kuntz K M, Weiss S T, Fuhlbrigge A L. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007; 120: 1146–1152
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006; 22: 1765–1776
   PubMed Web of Science ®Google Scholar
• Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma. Allergy 2007; 62: 149–153
   PubMed Web of Science ®Google Scholar
• Brown R, Turk F, Groot M, Dale P. Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to The Netherlands. Eur Respir J 2007; 30(suppl 51)194s, P1187
   Google Scholar